26 results about "ACUTE INFLAMMATIONS" patented technology

The invention belongs to the technical field of medicinal chemistry, and discloses a modular preparation method and application of a protein degradation agent targeting soluble epoxide hydrolase (sEH). The derivative has a structural general formula as shown in a formula (I), wherein X and Y substituent groups can be randomly combined. The compound can effectively degrade sEH level in cells and living bodies, and shows a remarkable protective effect on acute liver inflammation of mice in the living bodies. Particularly, the compound shows excellent degradation activity (EC50 = 2.9 nM) in 1d, can quickly relieve acute inflammation induced by LPS, and can be used for research and development of drugs for acute inflammation related diseases.

This invention discloses a *Lactobacillus plantarum* YBE2 and its applications. The *Lactobacillus plantarum* provided by this invention, which produces a high amount of extracellular polysaccharides primarily composed of rhamnose, can simultaneously degrade different types of bile salts, including specifically hydrolyzing glycocholic acid. It also exhibits cholesterol-lowering and acute inflammation-relieving effects. Furthermore, *Lactobacillus plantarum* YBE2 can reduce fat deposition in the abdomen of caged broilers, increase intramuscular fat, promote fatty acid deposition in muscles, and reduce plasma total bile acids, triglycerides, and low-density lipoprotein cholesterol. This significantly improves lipid metabolism and muscle quality in poultry, and can be widely applied in caged broiler farming to promote healthy poultry farming and improve farming efficiency.

This invention relates to the field of intelligent medical technology, and more particularly to a method for early warning of intestinal fibrosis in Crohn's disease based on a large model. The method includes: acquiring intestinal MRI image sequences of Crohn's disease patients; inputting the intestinal MRI image sequences into a pre-trained large model for intestinal structure analysis to locate the initial intestinal fibrosis region; determining whether the degree of intestinal luminal stenosis in Crohn's disease patients meets the standard based on the intestinal stenosis progression index, and adjusting the feature contrast threshold of the large model based on the difference; determining whether the acute inflammation masking effect of Crohn's disease patients is adequate based on intestinal wall edema characterization parameters, and adjusting the T2-weighted imaging modal weights of the large model based on the relative difference; and determining whether the patency of the fibrotic permeation channel in Crohn's disease patients is adequate based on the fibrotic permeation resistivity, and adjusting the boundary loss weights of the large model based on the ratio. This invention improves the accuracy of early warning of intestinal fibrosis in Crohn's disease.

The invention discloses an effective part for chemoradiotherapy-induced oral mucositis in traditional Chinese medicinal material white flower and a preparation process of the effective part. The effective part is identified as a flavonoid component through standard substance spectrogram comparison. Tests prove that the production process of the effective part is practical and feasible, and the total flavonoids in the finally obtained extracting solution are greater than or equal to 50%. Besides, pharmacodynamic studies show that the effective part has a remarkable bacteriostasis effect on staphylococcus aureus, escherichia coli and candida albicans, the bacteriostasis rate is larger than or equal to 80%, the effective part has a remarkable treatment effect on rat oral mucosa acute inflammation caused by chemoradiotherapy, and the application prospect of the effective part in the adaptation disease is shown.

The present application relates to treatment of nasal cavity inflammation and mucus hypersecretion. One aspect of the present invention is a method of treatment of rhinitis and rhinosinusitis, wherein the treatment reduces nasal stuffiness, nasal congestion, and phlegm secretion. Reduction of phlegm secretion from the nasal cavity into the pharynx can also reduce cough frequency from infectious and allergic rhinitis. In the preferred embodiment, FEMA 4557, is an example of a molecule, topically applied to the nasal mucosa, that can be used to treat rhinitis. FEMA 4557 is a potent non-irritating suppressor of acute inflammation in the nasal cavity and sinuses, a property not previously described for other topical cooling agents. Thus, FEMA 4557 and related analogs may have therapeutic utility for treating nasal inflammation and mucus hypersecretion.

The invention belongs to the technical field of biology, and discloses application of a composition of neoagaro-oligosaccharide and astaxanthin in preparation of a transdermal drug for treating osteoarthritis and a composite gel preparation. The composition provided by the invention comprises neoagaro-oligosaccharide, astaxanthin, carbomer and alginate in a mass ratio of (1-10): (1-10): (0.01-0.5): (0.1-1), and can realize efficient enrichment of neoagaro-oligosaccharide and astaxanthin in an articular cavity through a substance diffusion path of skin penetration, deep tissue diffusion, joint capsule permeation and articular cavity enrichment, so that the content of neoagaro-oligosaccharide and astaxanthin in the articular cavity is improved, and the content of astaxanthin in the articular cavity is reduced. The new agar oligosaccharide and the astaxanthin have an excellent synergistic effect, so that the acute inflammation symptom of gouty osteoarthritis can be efficiently relieved, the progress of the disease course is blocked, the pathological change of joint tissue is repaired, and the new agar oligosaccharide and the astaxanthin have an excellent application prospect in preparation of the transdermal medicine for treating osteoarthritis.

Methods for treating acute conditions (e.g., acute conditions comprising acute inflammation), such as cytokine release syndrome, sepsis and acute kidney injury using lipid binding protein-based complexes.

The application discloses a three-layer time sequence regulation type inflammation targeting composite repair system for repairing endometrial injury and a preparation method and application thereof. The system is a three-layer composite structure, which comprises, from outside to inside, (1) an outer ROS response hydrogel layer loaded with anti-inflammatory drugs, which can respond to early high expression of active oxygen to rapidly degrade the drugs, so that acute inflammation is inhibited; (2) a middle layer of targeted delivery and metabolic repair, which is a M1 macrophage membrane pseudo-loaded drug liposome (NMN@M-Lipo), which is exposed after the degradation of the outer hydrogel, actively targets the inflammation lesion through the M1 membrane, and slowly releases nicotinamide mononucleotide (NMN) to restore cell energy metabolism; and (3) an inner layer of cell recruitment and regeneration, which is a decellularized matrix scaffold loaded with SDF-1 alpha, which continuously releases SDF-1 alpha to recruit endogenous stem cells in the later repair stage, and promotes functional regeneration of the endometrium. The application utilizes the time sequence microenvironment changes of endometrial repair, and realizes the cascade regulation of 'anti-inflammation first, metabolic repair second, and regeneration promotion third'. Animal experiments show that the system can significantly restore the reproductive function of the injured endometrium and improve the number of offspring.

The application discloses a high-temperature-resistant self-delivery circular RNA and a synthesis method and application thereof in preparation of anti-inflammatory drugs, and relates to the technical field of biological medicines.The nucleotide sequence of the high-temperature-resistant self-delivery circular RNA is shown as SEQ ID NO.1.Through nucleic acid extraction and high-throughput sequencing analysis on the decoction of Radix Curcumae, combined with a reverse splicing site identification method, a specific circular RNA is screened and named as circW77.Further research shows that the circW77 can stably exist in a 100 DEG C environment and can significantly inhibit the expression of inflammation-related factors, thereby playing an anti-inflammatory role.Through verification of an in-vitro cell inflammation model, it is found that the circW77 can enter cells without the aid of a carrier and can effectively reduce the transcription and secretion of proinflammatory factors;in-vivo research shows that the circW77 can relieve acute inflammation and non-alcoholic fatty liver inflammation.

The invention provides application of plant lactobacillus in prevention and / or treatment of acute inflammation caused by LPS, and relates to the technical field of microorganisms, for mice with acute inflammation caused by LPS, plant lactobacillus DY6 can inhibit immune system transition activation and lymphocyte abnormal proliferation by adjusting blood routine indexes and visceral organ indexes; the anti-inflammatory effect is achieved by down-regulating inflammatory factors and neutrophil infiltration markers and inhibiting a TLR4 signal channel; redox balance is adjusted, intestinal flora unbalance is improved, and the effect of preventing and / or treating acute inflammation caused by LPS is achieved.

The application provides a fast-acting flunixin meglumine injection and a preparation method thereof, and belongs to the technical field of veterinary medicine, and contains the following components: flunixin meglumine 5-10 (w / v) %, alpha-pyrrolidone 10-30 (w / v) %, hydrophilic solvent 0.5-1 (w / v) %, antioxidant 0.1-0.3 (w / v) % and the balance of water for injection. The application takes flunixin meglumine as the main drug, matches alpha-pyrrolidone as a solvent and a targeting guide distribution component, uses a hydrophilic solvent to assist dissolution and promote absorption, and uses an antioxidant to inhibit the oxidative degradation of the main drug, so that the dissolution and absorption rate of the main drug and the target tissue distribution efficiency can be effectively improved, the storage stability can be ensured, the bacterial endotoxin and the injection site redness rate meet the requirements, the acute inflammation and pain of livestock and poultry can be quickly and efficiently relieved, and the demand for instant intervention in large-scale breeding can be met.

The invention provides bacteriostatic gel for women and a preparation method thereof, and belongs to the technical field of gynecological gel. The gel comprises 97%-99% of a multi-layer structure base material and 1%-3% of a natural plant effective component. The effective components comprise seven natural components such as a fructus cnidii extract, a helichthys italica extract and a radix sophorae flavescentis extract, and the base material comprises multiple layers of hydrogel. In the use process of the bacteriostatic gel for women, the fructus cnidii extract and the radix sophorae flavescentis extract can directly kill pathogenic bacteria of bacterial vaginitis and have an inhibition effect on HPV viruses, and the tea leaf extract and the psidium guajava leaf extract have antioxidant and bacteriostatic characteristics, so that the capacity of removing harmful microorganisms can be further enhanced. And the base material comprising multiple layers of hydrogel not only can enable bacteriostatic and anti-inflammatory components to continuously act on a focus part and improve the treatment effect on vaginitis and vulvitis, but also can reduce direct stimulation of subsequent effective components on sensitive mucous membranes, and is especially suitable for mucous membrane fragile scenes such as gynecologic operations and acute inflammation stages.

The invention relates to the technical field of intelligent medicine, in particular to a Crohn disease intestinal fibrosis condition early warning method based on large model driving, which comprises the following steps: acquiring an intestinal MRI image sequence of a Crohn disease patient; inputting the intestinal MRI image sequence into a pre-trained intestinal structure analysis large model, and positioning the position of an initial intestinal fibrosis region; determining whether the intestinal lumen stenosis degree of the patient with the Crohn disease reaches the standard or not based on the intestinal lumen stenosis progress index, and determining a feature comparison threshold value for adjusting the large model according to the difference value; determining whether the acute inflammation shielding effect of the patient with the Crohn disease is qualified or not based on the intestinal wall edema characterization parameters, and determining and adjusting the T2 weighted imaging modal weight of the large model according to the relative difference; and determining whether the fibrosis seepage channel smoothness of the patient with the Crohn disease is qualified or not based on the fibrosis seepage resistivity, and determining and adjusting the boundary loss weight of the large model according to the ratio. The early warning accuracy of the intestinal fibrosis condition of the Crohn's disease is improved.

The application discloses a strong external use Chinese herbal medicine composition and a preparation method and application thereof, and belongs to the technical field of external use Chinese herbal medicine preparations. The composition is prepared by compounding active ingredients of genuine Chinese medicinal materials and compliant external use matrix auxiliary materials, is strict in compatibility, is balanced in medicinal properties, and contains core medicinal materials of safflower, twinleaf, dandelion, rhubarb and bloodfly, and has multiple effects of clearing heat and resolving toxins, promoting blood flow and removing blood stasis, removing swelling and relieving pain, removing corruption and promoting tissue regeneration, and inhibiting bacteria and repairing. The application adopts a standardized preparation process of water extraction and concentration, homogeneous mixing and sterile filling, has a simple process, high stability, and is suitable for industrialized batch production, and can be prepared into two types of external use dosage forms of gels and creams. The gel dosage form is refreshing and breathable, is suitable for exudation wound surfaces, acute inflammation stages and summer use; the cream dosage form is nourishing and slow-releasing, is suitable for deep layer stasis and swelling, dry and indurated wound surfaces and winter maintenance use, the product is suitable for a wide range of scenes, is gentle and safe in medicinal properties, and is outstanding in clinical practicability and market value.

The invention belongs to the technical field of biomedicine, and particularly relates to an acute plateau low-pressure low-oxygen lung injury mouse model building method which comprises the following steps: selecting SPF-level male SD (Sprague Dawley) rats for adaptive feeding; performing low-oxygen sensitivity pretreatment on the rats after the adaptive feeding is finished; debugging the closed low-pressure oxygen cabin to an initial standard state, putting the pretreated rat into the closed low-pressure oxygen cabin, and closing the cabin door; performing staged low-pressure and low-oxygen synergistic exposure on the rats in the cabin, and obtaining an acute plateau low-pressure and low-oxygen lung injury rat model after the exposure is finished; according to the method, a staged low-pressure low-oxygen collaborative exposure design of pressure dominated low oxygen and oxygen concentration collaborative low oxygen is adopted, so that the core characteristic that the natural plateau oxygen partial pressure is gradually reduced along with the altitude is completely reproduced; the periodic fluctuation mode of the oxygen concentration cooperation stage further fits the oxygen concentration change of the real plateau environment, and it is ensured that the model can truly reproduce the progressive pathological process from the initial hypoxia stress to the acute inflammation injury.

The present application relates to the technical field of pharmaceutical chemistry, in particular to a preparation method and application of a berberine and isovitexin nanomedicine. The application is used in the preparation of a drug for treating diseases related to inflammation mediated by neutrophils. The berberine and isovitexin or the structural analogues of berberine and isovitexin form nanoparticles in a carrier-free form through self-assembly. The berberine and isovitexin nanomedicine has a synergistic anti-inflammatory and antioxidant effect, can efficiently inhibit key inflammatory mediators, realize high-efficiency anti-inflammatory and antioxidant synergy, and significantly improve the effect of preventing and treating acute inflammation.

The invention provides a traditional Chinese medicine ointment for reducing swelling, removing stasis and relieving pain and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine ointment provided by the invention has the remarkable effects of promoting blood circulation to remove blood stasis and relieving swelling and pain, can quickly relieve pain and alleviate swelling, and is suitable for various common inflammation and pain symptoms, such as parotitis, furuncle, scapulohumeral periarthritis and lumbar muscle strain; based on traditional Chinese medicine experience, the traditional Chinese medicine composition is simple in preparation process, convenient to use, capable of improving symptoms of patients and reducing pain within a short time without complex operation, high in safety and free of definite adverse reaction, has wide clinical application prospects and popularization value, and is beneficial for making up for the defects of modern medicine in part of chronic diseases and acute inflammation.

The invention discloses a preparation method and application of a quinazolinone-diketopiperazine heterozygote BRD4 inhibitor, belongs to the technical field of medicines, and particularly relates to the quinazolinone-diketopiperazine heterozygote BRD4 inhibitor shown in a general formula (I), pharmaceutically acceptable salt or stereoisomer thereof, and R1-R8, X, Y, Z or W are defined in the specification. The invention also relates to a preparation method of the compounds, and a pharmaceutical preparation or a pharmaceutical composition containing the compounds. The quinazolinone-diketopiperazine heterozygote BRD4 inhibitor provided by the invention has strong inhibitory activity (IC50 = 0.92 nM) and high selectivity (170323 times) on a second bromo-domain, which is stronger than that of a clinical test drug RVX-208 (17 times), and NO generation inhibitory activity is stronger than that of RVX-208, so that the quinazolinone-diketopiperazine heterozygote BRD4 inhibitor is expected to be applied to preparation of drugs for preventing or / and treating inflammation, and has broad application prospects. The compound can be particularly applied to preparation of drugs for preventing or / and treating acute inflammation (such as septicemia), and has a remarkable medicinal prospect.

The invention provides a method for regulating and controlling hematopoietic balance based on a Jak2 / Stat3-Hif1a signal channel and application of the method, and belongs to the field of biotechnology and medicine. According to the method, by regulating and controlling a Jak2 / Stat3-Hif1a signal channel, hematopoietic system unbalance caused by factors such as acute inflammation or acute hypoxia is intervened or reversed. Aiming at the problems that in the prior art, mechanism cognition is not clear, intervention targets are not clear, pathway relevance research is insufficient and the like, the molecular mechanism of acute inflammation affecting hematopoietic balance is deeply explored, and the internal relation of a Jak2 / Stat3 pathway and Hif1alpha for regulating and controlling hematopoietic balance under the acute stress condition is disclosed. The invention can be applied to preparation of medicines for treating blood system diseases caused by factors such as acute inflammation and hypoxia, particularly provides a targeted intervention strategy for accurately correcting hematopoietic lineage migration aiming at diseases such as sepsis-related anemia, and has important clinical application value.

The application belongs to the technical field of biological medicine, and discloses a tumor local acute inflammation inducer, a preparation method and application thereof. Specifically, extracted bacterial outer membrane vesicles are loaded into prepared temperature-sensitive hydrogel for in-situ injection treatment of common clinical solid tumors, such as breast cancer, melanoma, colorectal cancer and the like. The temperature-sensitive hydrogel loaded with bacterial outer membrane vesicles constructed in the application induces acute inflammation at the tumor site, effectively activates anti-tumor immunity, and improves the immunosuppressive microenvironment; at the same time, the temperature-sensitive hydrogel causes rupture of tumor blood vessels, and can be combined with photothermal therapy to further eradicate tumors; and the temperature-sensitive hydrogel limits acute inflammation in the tumor, improves biological safety, and provides a new strategy for development of in-situ tumor treatment preparations.

The invention discloses a biomarker combination for distinguishing kidney transplantation post-transplantation plant function delay duration and application of the biomarker combination. The combination consists of IL-15, CCL3, IL-7, CCL20 and IL-5 proteins, and can optionally comprise metabolites such as alpha-ketoglutaric acid and the like. Targeted proteomics and metabonomics analysis discovers that short-term DGF (SDGF) is characterized by acute inflammation and innate immune activation, and long-term DGF (LDGF) shows chronic immunoregulation accompanied by amino acid and energy metabolism disorder. Based on the combination, the invention further provides a corresponding in-vitro detection kit, a non-diagnostic distinguishing method and a data processing device. The early-stage accurate risk stratification of the DGF patient can be realized, a key basis is provided for clinical intervention decision, and the method has important clinical application value.

This article discloses methods for local expression and administration of RNA molecules at sites of acute inflammation, methods for treating tissue or organ damage in subjects characterized by sites of acute inflammation in tissues or organs, methods for treating subjects with sites of acute inflammation in tissues or organs, methods for treating tissue damage in the heart or brain in subjects caused by local ischemia, and medical products or kits suitable for administration and local expression at sites of acute inflammation.

The invention provides an application of a tobacco bean extract in preparation of an anti-inflammatory and analgesic external medicine, and in a chronic / acute inflammation model, the tobacco bean extract can effectively relieve mouse atopic dermatitis / ear inflammation symptoms induced by dinitrochlorobenzene (DNCB) / xylene; in the aspect of analgesic effect, the tobacco bean extract can relieve mouse pain response caused by hot plate stimulation and prolong the pain threshold latency period; mechanism research shows that the tobacco bean extract can significantly inhibit expression of various inflammation-related cytokines; therefore, the tobacco bean extract can obviously improve various acute and chronic inflammations, can relieve nerves, and has the potential of treating inflammations and inflammatory pain. Besides, the safety evaluation result shows that no obvious toxic reaction is caused in the experimental dose range, the toxicity burden caused by the inducer can be reduced in a disease model, and the safety and the application prospect are good.

The application provides a drug-loaded nanoparticle Cor@PDA-PEG@CD11b and a preparation method and application thereof, the preparation method comprises the following steps: S1, mixing cordycepin solution and PDA aqueous solution, so that the cordycepin and the PDA form a complex Cor@PDA through π-π stacking effect; S2, the obtained complex Cor@PDA is modified by PEG to prepare a complex Cor@PDA@PEG; S3, the obtained Cor@PDA@PEG is dispersed in a buffer solution, and an anti-CD11b antibody is added; after reacting for 24h, centrifugation, washing, collecting the precipitate, and drying, the Cor@PDA-PEG@CD11b is obtained. The drug-loaded nanoparticle Cor@PDA-PEG@CD11b prepared by the application provides a new idea and direction for the treatment of sepsis-related lung injury; through the characteristics of the PDA nanoparticles, the cordycepin is released in a controlled manner, and the problem that the cordycepin is rapidly oxidized and inactivated after entering the body is avoided, the bioavailability is improved, the specific antibodies on the surface of immune cells and the physiological characteristics are utilized, the immune cells are quickly and chemotactically recruited to the inflammatory injury site in the early stage of acute inflammation, the drug is quickly and accurately targeted, and the sepsis lung injury is reduced.

The present invention provides compounds used for the treatment of acute conditions including sepsis, sepsis-associated AKI, ischemia / reperfusion AKI, and CSA AKI, as well as CRS, such as CRS associated with immunotherapy and CRS secondary to infections like COVID-19. [Solution] A lipid-binding protein-based complex is provided for use in a method of treating an acute condition, the method comprising the step of administering a high dose of the lipid-binding protein-based complex to a subject in need thereof, the acute condition may include acute inflammation.

The invention provides a dissoluble microneedle loaded with colchicine and iguratimod ethosome nano-drugs and a construction method, the dissoluble microneedle comprises a needle body and a substrate, the substrate and the needle body both contain colchicine and iguratimod ethosome drugs, the dissoluble microneedle provided by the invention achieves the purpose of effectively treating gout, and the dissoluble microneedle has the advantages that the dissoluble microneedle can be used for treating gout; the traditional Chinese medicine composition can quickly relieve acute inflammation caused by gout diseases, has the effects of easing pain and resisting inflammation, repairs bone injury, and reduces gastrointestinal toxicity of colchicine and liver injury risk of iguratimod; according to the construction method of the dissoluble microneedle loaded with colchicine and iguratimod ethosome nano-drugs, the problems of drug degradation and ethosome agglomeration possibly caused by the difference of physicochemical properties of colchicine and iguratimod are solved fundamentally, the loss of drugs during mixing can be reduced, and the dispersity of ethosome can be optimized; the invention belongs to the technical field of preparation of nano-drugs, and is applied to preparation of drugs for treating gout.